T細胞リンパ腫の世界市場-2023-2030

市場概要

T細胞リンパ腫市場は、2022年に14億8,520万米ドルに達し、2030年には最大27億8,780万米ドルに達することで有利な成長を遂げると予測されます。T細胞リンパ腫市場は、予測期間（2023年～2030年）に8.4%のCAGRを示すと予測されています。

T細胞リンパ腫は、末梢性T細胞リンパ腫とT細胞リンパ芽球性リンパ腫の2種類に分類されます。T細胞リンパ腫は、化学療法、放射線療法、免疫療法、抗ウイルス薬、幹細胞移植、その他の治療法で治療することができます。

また、T細胞リンパ腫市場の成長は、放射線によるリンパ腫がん発症率の上昇、T細胞リンパ腫特異的な治療法の増加、自己免疫疾患によるリンパ腫のリスクなどに起因しています。

市場力学

世界のがんの有病率の増加

がんの有病率の増加は、T細胞リンパ腫の市場機会に影響を与える促進要因の1つです。また、ヘルスケアインフラへの投資の増加や、T細胞リンパ腫市場の拡大につながる老年人口の増加も要因の一つです。

WHOによると、がんは世界の主要な死因であり、2020年には約1,000万人、つまり6人に1人の死亡を占めるとされています。毎年、約40万人の子どもたちががんを発症しています。最も一般的ながんは、国によって異なります。

高額な治療費と長い治療期間

T細胞リンパ腫の治療は、その独特の作用機序から非常に高額であり、回収や製造工程も総費用に上乗せされます。また、治療費の高さは、患者さんの基準による病気のレベルや必要な治療のレベルによって、患者さんごとに異なってきます。

COVID-19の影響分析

COVID-19の流行は、がん治療サービスの混乱やがん治療のための臨床試験の停止により、予測期間中の世界のT細胞リンパ腫市場の動向にマイナスの影響を及ぼしました。

COVID-19の流行により、皮膚リンパ腫の患者は、病院へのアクセスが困難であったり、利用可能なヘルスケアリソースが不足していたりして、重要な診断検査や治療を受けられないリスクが高まっています。

目次

第1章 調査手法とスコープ

• 調査手法
• 調査目的および調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 世界のがん罹患率の増加
  • 抑制要因
    • 高額な治療費と治療期間の長期化
  • 機会
    • T細胞リンパ腫市場への投資と研究資金の増加
  • 影響分析

第5章 産業分析

• ポーターの5フォース分析
• サプライチェーン分析
• 価格分析
• 法規制の分析

第6章 COVID-19の分析

第7章 薬効分類別

• 末梢性T細胞リンパ腫
• 皮膚T細胞リンパ腫
• 未分化大細胞リンパ腫
• その他

第8章 治療別

• 放射線療法
• 化学療法
• 標的療法
• 外科手術
• 幹細胞移植
• その他

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋地域
• 中東・アフリカ地域

第10章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A（合併・買収）分析

第11章 企業プロファイル

• Johnson & Johnson
• Novartis AG
• Bristol Myers Squibb Company
• Merck & Co Inc
• F.Hoffmann La Roche Ltd
• Acrotech Biopharma
• GlaxoSmithKline Plc
• Spectrum Pharmaceuticals

第12章 付録

Market Overview

The T-Cell Lymphoma Market reached US$ 1,485.2 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 2,787.8 million by 2030. The T-cell lymphoma market is expected to exhibit a CAGR of 8.4% during the forecast period (2023-2030).

T-cell lymphoma is classified into two types: peripheral T-cell lymphoma and T-cell lymphoblastic lymphoma. T-cell lymphoma can be treated with chemotherapy, radiotherapy, immunotherapy, antiviral medication, stem cell transplantation, and other therapies.

The growth of the T-cell lymphoma market is also attributed to the rise in lymphoma cancer incidence due to radiation, an increase in the number of T-cell lymphoma-specific therapies, and the risk of lymphoma due to autoimmune disorders.

Market Dynamics

Increase in Prevalence of Cancer Worldwide

The increase in the prevalence rate of cancer is one of the drivers that affect the T Cell lymphoma market opportunities. Another factor is increasing investment in healthcare infrastructure and the rising geriatric population that leads to the expansion of the T-cell lymphoma market.

According to WHO, cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. Each year, approximately 400,000 children develop cancer. The most common cancers vary between countries.

High Cost and Long Duration of Treatment

Treatment for T-cell lymphoma is very expensive because of its unique mechanism of action and the collections and manufacturing processes also add to the total costs. The high cost of the treatment also varies from patient to patient according to the level of disease and level of treatment required as per the patient standards.

COVID-19 Impact Analysis

The COVID-19 pandemic had a negative impact on the global T-cell lymphoma market trend over the projection period, owing to disruptions in cancer treatment services and the halt of clinical trials for cancer therapy.

Due to the COVID-19 epidemic, patients with cutaneous lymphomas were at an increased risk of missing receiving crucial diagnostic tests and treatments, either because hospitals were difficult for them to access or because of a lack of available healthcare resources.

Segment Analysis

The Chemotherapy Segment will Dominate the Market in the Forecast Period with around 40.8% Market Share

Chemotherapy is a common treatment for T-cell lymphoma because it inhibits and slows the proliferation of cancer cells. In addition to surgery and radiation therapy, chemotherapy can affect the entire body. These treatments can destroy or eliminate cancer cells in a specific area of the body.

Also, a combination chemotherapy regimen, such as CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), CHOEP (etoposide, vincristine, doxorubicin, cyclophosphamide, and prednisone), or other multidrug regimens, is frequently used for treatment.

Geographical Analysis

North America is the Dominating Region During The Forecast Period Accounting For 42.4% In The Overall Market

The global T-cell lymphoma market is large in the North American region due to the high number of cases of T-cell lymphoma, the presence of strong rivals, and increased research in the North American region. Also, T-cell lymphomas are a subtype of Non-Hodgkin lymphoma and a rise in Non-Hodgkin lymphoma cases would likely increase the demand for new treatment options, assisting the market's growth.

Competitive Landscape

The major global players include: Johnson & Johnson, Novartis AG, Bristol Myers Squibb Company, Merck & Co Inc, F.Hoffmann La Roche Ltd, Acrotech Biopharma, GlaxoSmithKline Plc, and Spectrum Pharmaceuticals.

• Why Purchase the Report?
• To visualize the global T-cell lymphoma market segmentation based on the type, end user and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global T-cell lymphoma market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global T-cell lymphoma market report would provide approximately 92 tables, 108 figures and 195 pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Treatment
• 3.3. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increase in the prevalence of cancer worldwide
  • 4.1.2. Restraints
    • 4.1.2.1. High cost and long duration of treatment
  • 4.1.3. Opportunity
    • 4.1.3.1. Rise in the investments and research funding of T-cell lymphoma market
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Scenario Post COVID-19
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Drug Class

• 7.1. Peripheral T Cell Lymphoma
• 7.2. Cutaneous T Cell Lymphoma
• 7.3. Anaplastic Large Cell Lymphoma
• 7.4. Others

8. By Treatment

• 8.1. Radiotherapy
• 8.2. Chemotherapy
• 8.3. Targeted Therapy
• 8.4. Surgery
• 8.5. Stem Cell Transplantation
• 8.6. Others

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.5.1.1. The U.S.
    • 9.2.5.1.2. Canada
    • 9.2.5.1.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.5.1.1. Germany
    • 9.3.5.1.2. The UK
    • 9.3.5.1.3. France
    • 9.3.5.1.4. Italy
    • 9.3.5.1.5. Spain
    • 9.3.5.1.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.5.1.1. Brazil
    • 9.4.5.1.2. Argentina
    • 9.4.5.1.3. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.5.1.1. China
    • 9.5.5.1.2. India
    • 9.5.5.1.3. Japan
    • 9.5.5.1.4. Australia
    • 9.5.5.1.5. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. Johnson & Johnson
• 11.2. Novartis AG
• 11.3. Bristol Myers Squibb Company
• 11.4. Merck & Co Inc
• 11.5. F.Hoffmann La Roche Ltd
• 11.6. Acrotech Biopharma
• 11.7. GlaxoSmithKline Plc
• 11.8. Spectrum Pharmaceuticals

LIST NOT EXHAUSTIVE

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us